X

Thank you for sharing!

Your article was successfully shared with the contacts you provided.
LOS ANGELES � Karen Barth Menzies, a leading personal injury lawyer who has sued pharmaceutical companies over the risks of suicide and violence in antidepressants, has left Baum, Hedlund, Aristei, Goldman & Menzies after 12 years to join Newport Beach, Calif.-based Robinson, Calcagnie & Robinson. Menzies, who has testified before the Food and Drug Administration and met with Congressional officials on the risks of antidepressants, served as lead counsel in the national multidistrict litigation involving the withdrawal effects of Paxil. She also has filed numerous lawsuits over similar risks in other types of antidepressants. Menzies said she couldn’t pass up the opportunity to work at Robinson, Calcagnie & Robinson. “I love the idea of getting involved with more types of cases,” she said. “And being able to be mentored by Mark Robinson I thought was a great career opportunity.” Last year, Robinson obtained a $51 million verdict in the first federal jury case against Merck & Co. Inc. involving Vioxx. Most recently, Menzies has served as the lead trial lawyer in cases alleging that the use of antidepressants causes birth defects. Those cases have since ballooned, prompting the firm to form a joint venture with Robinson, Calcagnie & Robinson, said Michael Baum, managing partner of Baum Hedlund. “The number and volume of birth defect cases became quite large, and it was becoming a project,” he said. “But we could do a joint venture on those cases and have the two firms work together and create a litigation team on those cases.” Baum Hedlund has filed 50 cases alleging various antidepressants caused birth defects, with another 100 potential cases in the wings, Baum said. The joint venture would allow both firms to share staff, documents and legal fees from the cases. Menzies is joining Robinson, Calcagnie & Robinson with fellow associate, Jennifer Liakos. With Menzies’ departure, Baum Hedlund plans to change its name, Baum said. The name, however, has yet to be decided.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]

 
Reprints & Licensing
Mentioned in a Law.com story?

License our industry-leading legal content to extend your thought leadership and build your brand.

 

ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.